The global oligonucleotide synthesis market size was estimated at USD 1.5 billion in 2017. Declining cost of sequencing has resulted in rising demand for custom-made nucleotides for desired sequence across research, genetic testing, drug development, and forensic applications. This, in turn, has fostered demand for oligonucleotide synthesis across various life science industries.
Oligonucleotide synthesis is an integral part of several ongoing genetic research studies. Rising investments in genetic research are anticipated to boost demand for custom synthesis of different classes of oligos including decoys, aptamers, immunostimulatory, antisense, siRNA, and miRNA.
Several major and emerging oligonucleotides manufacturers are expanding their businesses through collaboration with pharmaceutical manufacturers. For instance, in June 2017, CordenPharma International signed a strategic collaboration with GE Healthcare Dharmacon Inc. for development of an end-to-end oligonucleotide-based drug discovery solution.
A substantial number of oligos are under late phase clinical trials targeting various conditions such as cancer, cardiovascular diseases, muscle dystrophies, and ocular disorders. This anticipated regulatory approval for multiple oligonucleotide-based therapies is expected to propel the market.
Marketing approaches implemented in this market include direct selling and selling via distributors in specific countries. The market is expected to benefit from constant growth of genomics and gene editing markets, as advancement in genetic tools would simplify the synthesis of oligonucleotides.
Introduction of novel and robust synthesizers that enable rapid and large-scale production of long oligonucleotide sequences is driving the segment. However, there has been an increase in uptake of contract manufacturing services and consulting owing to various advantages associated with contract service providers, such as improved efficiency, cost-effective services, and rapid development of products. This is anticipated to foster the growth of the services segment.
Presence of wide array of reagents for detritylation/deblocking, oxidation, cleavage, purification/desalting, labeling, and modification of oligonucleotides has significantly contributed to the dominant share of this segment in 2017. The segment is also fueled by need for specific reagents at each step of synthesis and high cost.
PCR primers are widely used in drug development for target screening and identification. Presence of a robust pipeline of oligonucleotides-based therapeutics, including antisense therapeutics, DNA vaccines, and anti-viral agents, in various phases of clinical development has allowed PCR primers to enjoy the largest revenue share in the oligonucleotide synthesis market.
Increase in focus on targeted gene therapies has revolutionized treatment of incurable conditions caused by genetic mutations. Increase in demand for sequencing applications by clinical, diagnostic, academic, and drug development is witnessed by manufactures.
Pharmaceutical industries and biotechnology companies are focused on seeking alternative approaches for disease treatment. As a result, these companies are making significant use of oligonucleotides, as it offers an effective mode of action for treatment of various indications at comparatively lower development cost.
Furthermore, oligonucleotides play a vital role in overcoming challenges pertaining to efficient route of drug administration. This, in turn, is projected to increase manufacturing of oligonucleotide therapeutics, thereby enhancing the share of pharmaceutical and biotechnology companies in the global market.
Government and private entities are investing in development of academic and research infrastructure in emerging economies. This factor is expected to positively boost oligonucleotide adoption in academic research institutes. Surge in genomic research projects conducted by academic research institutes has enabled this segment to account for the dominant share in the market. Moreover, collaboration among major players and universities for development of novel approaches to cure chronic conditions through genetic medicine is expected to contribute to the growth of this segment.
Presence of innovators and key players in U.S. has resulted in higher penetration of products in the market. This has allowed North America to account for a significant revenue share in 2017. Furthermore, the strong foothold of North America in genomics, proteomics, oncology, diagnostic screening, and drug discovery has significantly contributed to maintaining its large share.
Asian countries are recognized as the fastest adopters of sequencing, array technology, and PCR products due to rapid progress in genomics studies and the healthcare sector. Japan and China are considered as the most attractive markets with respect to expansion and growth opportunities present in these countries. In addition, changing economic scenario, along with high investments in healthcare, life science-related research programs, and genetics, has encouraged global players to enter the Asia Pacific market, thus aiding its growth.
Some key companies operating in the market are Thermo Fisher Scientific, Inc.; Merck - Co., Inc.; GE Healthcare Dharmacon Inc.; Agilent Technologies; Bio-synthesis; Kaneka Eurogentec S.A.; Integrated DNA Technologies, Inc.; BioAutomation; and LGC Biosearch Technologies. The market is highly competitive due to rigorous strategies adopted by these players in order to capture a greater market share.
Various strategies adopted by these competitors include acquisition of players in emerging markets, distribution partnerships, and collaboration for development of novel technologies and products. For instance, in February 2017, Integrated DNA Technologies acquired GeneWorks Pty Ltd., an oligonucleotide manufacturer in Australia through its Singapore-based subsidiary.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2018 - 2025
Revenue in USD Million - CAGR from 2018 to 2025
North America, Europe, Asia Pacific, Latin America, MEA
U.S., Canada, Germany, U.K., Japan, China, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global oligonucleotide synthesis market report on the basis of product, application, end use, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Oligonucleotides, By Product Type
Oligonucleotides, By Nucleic Acid Type
Application Outlook (Revenue, USD Million, 2014 - 2025)
PCR Assays and Panels
Fluorescence In Situ Hybridization (FISH)
End-use Outlook (Revenue, USD Million, 2014 - 2025)
Academic Research Institutes
Pharmaceutical - Biotechnology Companies
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East and Africa (MEA)
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."